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Abstract: This work takes advantage of one of the hall-
marks of cancer, that is, the presence of tumor infiltrating
cells of the immune system and leukocyte-secreted en-
zymes, to promote the activation of an anticancer drug at
the tumor site. The peptidomimetic integrin ligand cy-
clo(DKP-RGD) was found to accumulate on the surface of
avb3 integrin-expressing human renal cell carcinoma 786-
O cells. The ligand was conjugated to the anticancer drug
paclitaxel through a Asn-Pro-Val (NPV) tripeptide linker,
which is a substrate of neutrophil-secreted elastase. In vi-
tro linker cleavage assays and cell antiproliferative experi-
ments demonstrate the efficacy of this tumor-targeting
conjugate, opening the way to potential therapeutic ap-
plications.
The conjugation of anticancer drugs to specific ligands, capa-
ble of selective binding to tumor-associated receptors, repre-
sents a widely explored strategy to improve the accumulation
of cytotoxic agents at the tumor site, sparing healthy tissues
and resulting in better therapeutic outcomes. Antibody–drug
conjugates (ADCs) represent the first-in-class in this oncology
area.[1] To date, four ADC products have gained marketing au-
thorization (Adcetris, Kadcyla, Mylotarg, and Besponsa), while
more than 50 are presently under clinical investigation.[2] Simi-
larly, anticancer agents have also been coupled to small li-
gands (e.g. , peptides/peptidomimetics,[3] vitamins,[4] steroids,[5]
and enzyme inhibitors),[6] targeting specific receptors overex-
pressed by cancer cells. An increasing body of evidences sug-
gests that these so-called small molecule–drug conjugates
(SMDCs)[7] may accumulate in the tumor mass homogeneously
and with high tumor/organ and tumor/blood ratios, potentially
showing better anticancer efficacy than conventional cytotoxic
agents and ADC products.[8] In general, these conjugates have
been designed to bind the target receptor on the surface of
cancer cells and to release the cytotoxic cargo in intracellular
compartments (e.g. , lysosomes), upon receptor-mediated inter-
nalization and selective cleavage of a linker (e.g. , a short pep-
tide sequence or a reducible disulfide bond) connecting the
targeting unit to the payload.[9]
Among the protein antigens that have been explored for
tumor targeting applications, integrin avb3 is a heterodimeric
transmembrane receptor overexpressed in a variety of cancer
types (such as melanoma, glioblastoma, renal cell carcinoma,
and tumors of lung, ovary, breast, prostate, and colon), where
it is involved in disease progression.[10] Upon the observation
that cyclic peptides bearing the Arg-Gly-Asp (RGD) sequence
are potential avb3 integrin ligands, a large number of RGD-
bearing peptides and peptidomimetics have been explored for
SMDC development.[11]
Within this frame, our group synthesized a cyclic peptidomi-
metic compound bearing the RGD integrin recognition motif
and a diketopiperazine (DKP) scaffold, as a low nanomolar avb3
integrin ligand (compound 1, Figure 1).[12] The ligand was suc-
cessfully linked to different cytotoxic payloads (i.e. , paclitax-
el,[13] camptothecin,[14] and a-amanitin)[15] and the resulting
conjugates maintained high affinity for the integrin receptor. In
line with literature data that reported evidence of internaliza-
tion of integrin ligands equipped with fluorescent dyes,[16] our
cyclo(DKP-RGD)-drug conjugates were endowed with suitable
linkers for selective payload release in intracellular compart-
ments of the cancer cells. The ability of these SMDCs to selec-
tively hit avb3-positive cells was quantified through in vitro cell
antiproliferative assays performed using cancer cell lines ex-
pressing the integrin receptor at different levels (i.e. , express-
ing vs. non-expressing cells). To our delight, some of these
SMDCs proved to be highly selective for the avb3-expressing
cells,[17] indicating that 1 effectively recognizes the integrin re-
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ceptor on the cancer cell membrane. However, the potency of
all our conjugates against avb3-positive cells proved to be sig-
nificantly lower (typically one order of magnitude) than that of
the free drug. This observation is in contrast with literature
data reporting the high potency of internalizing ADCs and
SMDCs,[18,19] and it may indicate a suboptimal endocytosis of
our ligand–drug conjugates. In order to confirm this hypothe-
sis and evaluate the internalization properties of the cyclo(DKP-
RGD) integrin ligand, we labeled it with the near-infrared (NIR)
dye sulfo-cyanine5 (sCy5, Figure 1). The ability of the resulting
conjugate cyclo(DKP-RGD)–sCy5 (2) to compete with biotinylat-
ed vitronectin for the binding to the isolated avb3 receptor
was measured. The low-nanomolar IC50 value obtained con-
firmed that integrin recognition was not affected by the conju-
gation with the probe (2, Figure 1). Moreover, we devised the
preparation of a negative control, possessing almost identical
physical-chemical properties, while showing negligible affinity
for the receptor. Inspired by the literature,[20] the Arg-Gly-Asp
tripeptide was mutated into a Arg-[bAla]-Asp sequence, giving
rise to the cyclo(DKP-RbAD) ligand 3 (Figure 1). In comparison
with the parent ligand 1, the new compound showed a dra-
matically lower integrin binding affinity (micromolar IC50 value)
and a similar result was obtained for the fluorescent conjugate
cyclo(DKP-RbAD)-sCy5 4 (Figure 1).
Confocal microscopy experiments were carried out with live
human cancer cells 786-O (renal cell carcinoma), expressing
avb3 integrin (as detected by Western blot analysis ; see Fig-
ure S1 in the Supporting Information), in the presence of con-
jugates 2 and 4. The uncoupled sulfo-cyanine5 probe was also
included in the experiment as additional control. As shown in
Figure 2, a fair accumulation of the cyclo(DKP-RGD)-sCy5 conju-
gate (2) on the membrane of cancer cells was detected, where-
as no significant intracellular uptake was observed. On the
other hand, no accumulation of control compounds cyclo(DKP-
RbAD)-sCy5 (4) and free sulfo-cyanine5 was detected neither in
intracellular compartments, nor on the cell surface.
Overall, this analysis confirmed that the integrin ligand cy-
clo(DKP-RGD) 1 accumulates on the cell membrane of avb3 in-
tegrin-expressing cancer cells, while it is poorly internalized by
receptor-mediated endocytosis. This finding may be related to
the antagonist behavior of 1, which has been found to display
inhibitory effects on the FAK/Akt integrin-activated transduc-
tion pathway and on integrin-mediated cell infiltration process-
es.[21] The elucidation of the link between the agonist/antago-
nist behavior of integrin ligands and the receptor-mediated in-
ternalization is currently a hot topic in this field.[22]
Interestingly, the importance of conjugate internalization has
been recently challenged.[23] Indeed, ADCs and SMDCs specific
to non-internalizing receptors (e.g. , collagen IV,[24] carbonic an-
hydrase IX,[25] fibrin,[26] and splice variants of fibronectin[27] and
tenascin-C)[28] were found to elicit strong antitumor responses
in vivo, while proving significantly less potent than the parent
drug in in vitro cell antiproliferative assays.[29] For these rea-
sons, we envisioned the preparation of a non-internalizing,
avb3 integrin-targeted conjugate, featuring a specific linker for
the extracellular release of the payload.
In 2002, researchers at Bayer developed a new SMDC, whose
linker consisted in the tripeptide Asn-Pro-Val (NPV), a specific
substrate of neutrophil elastase.[30] The latter is a serine pro-
Figure 1. Molecular structure of the avb3 integrin ligand cyclo(DKP-RGD) (1)
and its analog cyclo(DKP-RbAD) (3), alongside with their relative sulfo-cya-
nine5 (sCy5) conjugates cyclo(DKP-RGD)-sCy5 (2) and cyclo(DKP-RbAD)-sCy5
(4). Data of inhibition of biotinylated vitronectin binding to the avb3 recep-
tor are shown.
Figure 2. Confocal microscopy images of live avb3-expressing human renal cell carcinoma 786-O cells after exposure to conjugates 2 (A), 4 (B) and free sCy5
(C) (1 mmolL@1, exposure time=2 h). Accumulation at the cell membrane was detected only upon exposure to conjugate 2. No fluorescent signal was detect-
ed in the intracellular compartments for all compounds tested. Blue: Hoechst; Red: NIR dye.
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tease stored in azurophilic granules of neutrophils and re-
leased into the extracellular space upon infections or inflam-
mation stimuli. High levels of elastase have been reported in
primary tumors and metastasis, where it promotes oncogenic
signaling and inhibits tumor suppressors. As a result, elevated
neutrophil elastase levels correlate with poor prognosis in dif-
ferent types of solid tumors.[31] To the best of our knowledge,
no further investigations of this promising NPV peptide linker
have been reported in the literature. For these reasons, we de-
signed an extracellularly cleavable conjugate (5, Figure 3) in
which the avb3 integrin ligand cyclo(DKP-RGD) is connected to
paclitaxel (PTX) via a self-immolative spacer, the NPV linker and
a hydrophilic PEG4 spacer. Two additional conjugates were
prepared as negative controls : the cyclo(DKP-RGD)-NPv-PTX
conjugate (6), featuring the non-proteinogenic amino acid d-
valine, and the cyclo(DKP-RGD)-unc-PTX conjugate (7), in which
the tripeptide moiety is replaced by a proteolytically stable (or
“uncleavable”) tertiary amide bond. This panel of compounds
was designed to gain insights into the specificity of elastase
cleavage and the stability of the whole linker system. All syn-
thetic details and analytics are included in the Supporting In-
formation.
The affinity of compounds 5–7 for avb3 integrin was estimat-
ed as described previously and low-nanomolar values were ob-
tained throughout the series (Table 1).
To evaluate the cleavage of the tripeptide linker and the
subsequent paclitaxel release in the presence of neutrophil
elastase, conjugate 5 was treated with the enzyme in PBS solu-
tion at 37 8C, and metabolites were detected by HPLC-MS anal-
ysis. The enzymatic cleavage of the tripeptide linker was ob-
served over a 2 h period, resulting in the complete formation
of metabolite 10[32] (Figure 3), whereas the use of inactivated
enzyme did not lead to metabolite formation (Figure S2 in the
Supporting Information). The selectivity of linker cleavage was
analyzed by treating 5 with rat liver-derived lysosome extract,
composed of a mixture of proteolytic enzymes. The broad-
scope cysteine proteases inhibitor E-64 was used in this experi-
ment to gain insight into the effector enzymes involved in the
Figure 3. Molecular structures of the avb3 integrin-targeted conjugate cyclo(DKP-RGD)-NPV-PTX (5), of its diastereoisomer cyclo(DKP-RGD)-NPv-PTX (6), whose
linker bears d-valine (v), and of the uncleavable conjugate cyclo(DKP-RGD)-unc-PTX (7). Mechanism of PTX release upon linker cleavage is depicted, consisting
in the fast 1,6-elimination of the p-aminobenzyl carbamate 8, followed by amine cyclization in compound 10, which results in the formation of cyclic urea 11
and free Paclitaxel (12).
Table 1. Inhibition of biotinylated vitronectin binding to the avb3 recep-
tor.
Conjugate Structure avb3 IC50 [nm]
[a]
5 cyclo(DKP-RGD)-NPV-PTX 12.9:1.4
6 cyclo(DKP-RGD)-NPv-PTX 24.9:2.1
7 cyclo(DKP-RGD)-unc-PTX 5.8:1.2
[a] IC50 values were determined as the concentration of compound re-
quired for 50% inhibition of biotinylated vitronectin binding as estimated
by GraphPad Prism software. All values are the arithmetic mean: the
standard deviation (SD) of duplicate determinations.
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cleavage. Upon 2 h exposure to lysosome extract, conjugate 5
was digested only partially (Figure S4 in the Supporting Infor-
mation), possibly indicating the presence of elastase in the ly-
sosome extract.[33] This hypothesis was supported by the par-
tial formation of metabolite 10 also in the presence of the E-64
inhibitor, (Figure S4 in the Supporting Information) indicating
that cysteine proteases are not responsible for the cleavage of
the NPV linker.
Additionally, conjugate 5 was treated with mouse plasma at
37 8C, showing an excellent stability under these conditions
(t1/2=35.3 h, Figure S5 in the Supporting Information).
Following the protocol reported by Bayer,[30] the in vitro cell
antiproliferative activity of conjugates 5–7 was tested against
786-O cancer cells, in the presence or absence of elastase. Im-
portantly, Western blot analysis showed no significant elastase
expression in these cancer cells (see Figure S1 in the Support-
ing Information). This model assay aimed at evaluating the ex-
tracellular cleavage of the NPV linker upon activation of neu-
trophils and release of elastase in the extracellular tumor envi-
ronment, followed by the PTX internalization into cancer cells
by passive diffusion through the cell membrane. In the ab-
sence of elastase, conjugates 5–7 did not exhibit a significant
cytotoxic activity (IC50>5 mm, Table 2), whereas free PTX inhib-
ited cell proliferation at nanomolar concentrations (IC50=
35.8:16.7 nm). Interestingly, conjugate 5 displayed a >250-
fold increased activity (IC50=19.6:4.1 nm) upon addition of
elastase (50 nm), and the observed potency was comparable to
the one exhibited by free PTX under the same conditions
(IC50=29.5:7.6 nm). On the other hand, the presence of elas-
tase did not modify the original cell antiproliferative activity of
conjugates 6 and 7. This result indicates not only that the PTX
payload is inactive when it is not released from the targeting
vehicle, but also that the use of the natural amino acid l-Val at
the linker C-terminus is crucial for the recognition of the tri-
peptide sequence by elastase.
In conclusion, integrin ligands represent promising vehicles
for the selective release of anticancer drugs at the tumor site.
However, it is still not clear whether different RGD-based li-
gands may have different effects on the receptor internaliza-
tion and recycling in cancer cells. Upon the observation that
the integrin ligand cyclo(DKP-RGD) is not efficiently internalized
by avb3-expressing cancer cells, we focused on suitable strat-
egies for the delivery of anticancer agents in the extracellular
tumor environment. In this work, the peptide sequence NPV,
substrate of the serine protease elastase, has been investigated
as trigger for the release of paclitaxel from an avb3-targeted
conjugate. Ideally, the integrin recognition unit would drive
the conjugate accumulation at the tumor site, where the pro-
inflammatory stimuli result in the recruitment of tumor-infil-
trating leukocytes, such as neutrophils. The activation of the
latter promotes the release of elastase, which triggers the pay-
load release in the tumor microenvironment. As described else-
where,[23] this mode of activation may possess potential thera-
peutic benefits, since the free payload would diffuse in the
tumor mass, and act against a large variety of cells (e.g. , anti-
gen-negative cancer cells, endothelial and other cancer-associ-
ated host cells) leading to a localized damage. It has been re-
ported that lipophilic payloads are most suited for this strat-
egy, as the membrane permeability would facilitate the cyto-
toxic activity by the so-called “bystander effect.”[34] Our in vitro
data indicate that each individual unit of our SMDC (i.e. ,
ligand, linker, and drug) may efficiently act according to this
ideal mechanism of action. Moreover, the pro-inflammatory en-
vironment and the presence of infiltrating cells of the immune
system are well-established hallmarks of cancers.[35] It is there-
fore conceivable that elastase-activatable prodrugs may be
therapeutically active against a large variety of tumor types.
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